Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ultragenyx Pharmaceutical stock | $128.87

Own Ultragenyx Pharmaceutical stock in just a few minutes.

Fact checked

Ultragenyx Pharmaceutical Inc is a biotechnology business based in the US. Ultragenyx Pharmaceutical shares (RARE) are listed on the NASDAQ and all prices are listed in US Dollars. Ultragenyx Pharmaceutical employs 740 staff and has a trailing 12-month revenue of around USD$215.1 million.

How to buy shares in Ultragenyx Pharmaceutical

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ultragenyx Pharmaceutical. Find the stock by name or ticker symbol: RARE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ultragenyx Pharmaceutical reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$128.87, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ultragenyx Pharmaceutical, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ultragenyx Pharmaceutical. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Ultragenyx Pharmaceutical share price

Use our graph to track the performance of RARE stocks over time.

Ultragenyx Pharmaceutical shares at a glance

Information last updated 2020-12-01.
Latest market closeUSD$128.87
52-week rangeUSD$31.99 - USD$124.36
50-day moving average USD$105.7391
200-day moving average USD$86.6009
Wall St. target priceUSD$104.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-7.009

Buy Ultragenyx Pharmaceutical shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ultragenyx Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ultragenyx Pharmaceutical price performance over time

Historical closes compared with the close of $128.87 from 2020-12-09

1 week (2021-01-08) -14.42%
1 month (2020-12-15) -18.89%
3 months (2020-10-15) 37.43%
6 months (2020-07-15) 50.88%
1 year (2020-01-15) 111.30%
2 years (2019-01-15) 151.70%
3 years (2018-01-12) 169.60%
5 years (2016-01-15) 61.84%

Ultragenyx Pharmaceutical financials

Revenue TTM USD$215.1 million
Gross profit TTM USD$-262,649,000
Return on assets TTM -19.11%
Return on equity TTM -36.8%
Profit margin -119.19%
Book value $10.954
Market capitalisation USD$7.8 billion

TTM: trailing 12 months

Shorting Ultragenyx Pharmaceutical shares

There are currently 6.8 million Ultragenyx Pharmaceutical shares held short by investors – that's known as Ultragenyx Pharmaceutical's "short interest". This figure is 3.4% down from 7.1 million last month.

There are a few different ways that this level of interest in shorting Ultragenyx Pharmaceutical shares can be evaluated.

Ultragenyx Pharmaceutical's "short interest ratio" (SIR)

Ultragenyx Pharmaceutical's "short interest ratio" (SIR) is the quantity of Ultragenyx Pharmaceutical shares currently shorted divided by the average quantity of Ultragenyx Pharmaceutical shares traded daily (recently around 546825.92). Ultragenyx Pharmaceutical's SIR currently stands at 12.5. In other words for every 100,000 Ultragenyx Pharmaceutical shares traded daily on the market, roughly 12500 shares are currently held short.

However Ultragenyx Pharmaceutical's short interest can also be evaluated against the total number of Ultragenyx Pharmaceutical shares, or, against the total number of tradable Ultragenyx Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ultragenyx Pharmaceutical's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Ultragenyx Pharmaceutical shares in existence, roughly 100 shares are currently held short) or 0.1377% of the tradable shares (for every 100,000 tradable Ultragenyx Pharmaceutical shares, roughly 138 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ultragenyx Pharmaceutical.

Find out more about how you can short Ultragenyx Pharmaceutical stock.

Ultragenyx Pharmaceutical share dividends

We're not expecting Ultragenyx Pharmaceutical to pay a dividend over the next 12 months.

Have Ultragenyx Pharmaceutical's shares ever split?

Ultragenyx Pharmaceutical's shares were split on a 1:3 basis on 17 January 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ultragenyx Pharmaceutical shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Ultragenyx Pharmaceutical shares which in turn could have impacted Ultragenyx Pharmaceutical's share price.

Ultragenyx Pharmaceutical share price volatility

Over the last 12 months, Ultragenyx Pharmaceutical's shares have ranged in value from as little as $31.99 up to $124.36. A popular way to gauge a stock's volatility is its "beta".

RARE.US volatility(beta: 2.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ultragenyx Pharmaceutical's is 2.1629. This would suggest that Ultragenyx Pharmaceutical's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Ultragenyx Pharmaceutical overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site